KMT2A and B-cell non-Hodgkin lymphoma: Evidence from a study on B-cell lymphoma indicated that MLL-rearranged acute lymphoblastic leukemia could be treated with FX1, with its safety and efficacy validated at the animal level (Hurtz et al., 2019).